Cas:5855-56-1 2-Chloro-4-phenylquinoline manufacturer & supplier

We serve Chemical Name:2-Chloro-4-phenylquinoline CAS:5855-56-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-Chloro-4-phenylquinoline

Chemical Name:2-Chloro-4-phenylquinoline
CAS.NO:5855-56-1
Synonyms:2-chloro-4-phenyl-quinoline;HMS1414K02;2-Chlor-4-phenyl-chinolin
Molecular Formula:C15H10ClN
Molecular Weight:239.70000
HS Code:2933499090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:378.4ºC at 760 mmHg
Density:1.235g/cm3
Index of Refraction:1.66
PSA:12.89000
Exact Mass:239.05000
LogP:4.55520

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-chloro-4-phenyl-quinoline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Chlor-4-phenyl-chinolin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-chloro-4-phenyl-quinoline Use and application,HMS1414K02 technical grade,usp/ep/jp grade.


Related News: In the process of fine chemical industry transfer, intermediates are a very important category, and they are also the main link for China to undertake transfers. 2-Chloro-4-phenylquinoline manufacturer Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 2-Chloro-4-phenylquinoline supplier The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term. 2-Chloro-4-phenylquinoline vendor The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term. 2-Chloro-4-phenylquinoline factory This also includes its anti-tau pipeline, with the FDA’s approval having “implications for AD programmes targeting Tau,” according to Jefferies.